Pfizer
Pharmaceutical giant Pfizer develops and produces medicines and vaccines for a variety of chronic diseases and conditions. The company, founded in 1872, has several blockbuster products that each generate more than $1 billion in revenue per year, including Prevnar 13, a pneumococcal conjugate vaccine; Ibrance, a breast cancer treatment; and Eliquis, which helps prevent strokes in at-risk people. On Dec. 11, 2020, to help combat the coronavirus pandemic, the U.S. Food and Drug Administration authorized Pfizer and BioNTech’s COVID-19 vaccine for emergency use, the first of three given a green light in the U.S. As of May 26, half of all adults in the U.S. have been fully vaccinated against COVID-19, in large part due to the Pfizer-BioNTech shot.
Daniel Acker—Bloomberg via Getty Images
Company Information
As of 2/1/2023
Country
U.S.
Headquarters
New York City
Industry
Pharmaceuticals
CEO
Albert Bourla
Website
Company Type
Public
Ticker
PFE
Revenues ($M)
$100,330
Profits ($M)
$31,372
Market Value ($M)
$253,217
Employees
79,000
Figures are for fiscal year ended Dec. 31, 2022. Market value as of Jan. 20, 2023. Sources: Bloomberg; S&P Global.
World's Most Admired Companies
Sector
Natural resources
Industry
Pharmaceuticals
Current All-Star Rank
8
Previous All-Star Rank
4
Industry Rank
4
Previous Industry Rank
4
Overall Score
7.53
Innovation
5
People Management
3
Use of Corporate Assets
6
Social Responsibility
5
Quality of Management
2
Financial Soundness
2
Long-Term Investment Value
6
Quality of Products/Services
2
Global Competitiveness
3
Key Financials (Last Fiscal Year)
$ millions
% change
Revenues ($M)
-
-
Profits ($M)
-
-
Assets ($M)
-
-
Total Stockholder Equity ($M)
-
-
Profit Ratios
Profit as % of Revenues
-
Profits as % of Assets
-
Profits as % of Stockholder Equity
-
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)
-
EPS % Change (from 2020)
-
EPS % Change (5 year annual rate)
-
EPS % Change (10 year annual rate)
-
Total Return
Total Return to Investors (2021)
-
Total Return to Investors (5 year, annualized)
-
Total Return to Investors (10 year, annualized)
-
Lists ranking Pfizer
Latest news for Pfizer
- Health
Pfizer is on the hunt for new blockbuster drugs, backed by its COVID fortuneNovember 8, 2022, 2:15 PM UTC - Europe
Europe’s drug regulator set to approve Moderna and Pfizer Omicron boosters this weekAugust 31, 2022, 4:09 PM UTC - Newsletters
How Zoetis’s CEO is catering to the hands-on millennial pet ownerAugust 30, 2022, 12:16 PM UTC - Health
Pfizer-BioNTech ‘surprised’ by Moderna lawsuit alleging they copied COVID-19 vaccine technologyAugust 26, 2022, 4:09 PM UTC
- Novavax CEO on why his Covid vaccine is "demonstrably better" than Pfizer and Moderna;7:03Series, On Leading;
- Brainstorm Health 2022 - Burned Out: Tackling Well-Being And Mental Resilience In The Workplace;19:05Conferences, Brainstorm Health;
- Brainstorm Health 2022 - Leveraging New Frontiers: The Importance Of A Global Strategy ;21:29Conferences, Brainstorm Health;
- FDA recommends second booster for ages 50 and older;1:28News, Raw;